NasdaqGM - Nasdaq Real Time Price USD

89bio, Inc. (ETNB)

7.70

-0.09

(-1.16%)

At close: May 9 at 4:00:00 PM EDT

7.70

0.00

(0.00%)

After hours: May 9 at 4:05:11 PM EDT

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company’s common stock to seven new empl

GlobeNewswire yesterday

ETNB
-1.16%
89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time:

GlobeNewswire 4 days ago

ETNB
-1.16%
89bio Reports First Quarter 2025 Financial Results and Corporate Updates

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2

GlobeNewswire 9 days ago

ETNB
-1.16%
Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa,

Investing.com last month

MRNA

ETNB
-1.16%

APOG
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89BIO (ETNB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks last month

ETNB
-1.16%
89bio to Participate in the Leerink Partners Global Healthcare Conference

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meeting

GlobeNewswire 2 months ago

ETNB
-1.16%
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now

GlobeNewswire 2 months ago

ETNB
-1.16%
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

ETNB
-1.16%
Should You Buy 89BIO (ETNB) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks 2 months ago

ETNB
-1.16%
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership

Key Insights Significantly high institutional ownership implies 89bio's stock price is sensitive to their trading...

Simply Wall St. 3 months ago

ETNB
-1.16%
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced underwritten public offering of 25,957,142 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 4,285,714 shares, at a

GlobeNewswire 3 months ago

ETNB
-1.16%
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 21,671,428 shares of its common stock at a public offering price per share of $8.75 and, in lieu of common stock to a certain investor, pre-fund

GlobeNewswire 3 months ago

ETNB
-1.16%
Why 89bio Stock Lagged the Market Today

89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue. Just after market close on Monday, 89bio divulged that it intends to raise as much as $287.5 million from a secondary stock issue.

Motley Fool 3 months ago

ETNB
-1.16%

^GSPC
Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.

Investor's Business Daily 3 months ago

AKRO

ETNB
-1.16%
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc

GlobeNewswire 3 months ago

ETNB
-1.16%
89bio Provides Business Update and Outlook for 2025

– Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024 – SAN FRANCISCO, Jan.

GlobeNewswire 3 months ago

ETNB
-1.16%
New Strong Sell Stocks for January 7th

ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.

Zacks 3 months ago

ETNB
-1.16%

ATUS

ASH
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where 89bio, Inc. (NASDAQ:ETNB) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is expanding quickly […]

Insider Monkey 5 months ago

ETNB
-1.16%
89bio to Participate in the 7th Annual Evercore HealthCONx Conference

SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor me

GlobeNewswire 5 months ago

ETNB
-1.16%
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafe

GlobeNewswire 5 months ago

ETNB
-1.16%

Performance Overview

Return	ETNB	S&P 500 (^GSPC)
YTD	-1.53%	-3.77%
1-Year	-15.48%	+8.55%
3-Year	+268.42%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

89bio, Inc. (ETNB)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in Upcoming Investor Conferences

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

Citi says SMid biotechs alternative to large caps as it starts coverage

Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Should You Buy 89BIO (ETNB) After Golden Cross?

Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Why 89bio Stock Lagged the Market Today

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio Provides Business Update and Outlook for 2025

New Strong Sell Stocks for January 7th

Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Performance Overview